
Binfeng Lu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6138953/publications.pdf Version: 2024-02-01



RINFENC LU

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
3	PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor. Clinical Cancer Research, 2016, 22, 1173-1184.	7.0	207
4	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. International Journal of Molecular Sciences, 2017, 18, 645.	4.1	193
5	Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+ T and NK Cells. Journal of Immunology, 2015, 194, 438-445.	0.8	185
6	An Increased Abundance of Tumor-Infiltrating Regulatory T Cells Is Correlated with the Progression and Prognosis of Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2014, 9, e91551.	2.5	169
7	ST2/IL-33-Dependent Microglial Response Limits Acute Ischemic Brain Injury. Journal of Neuroscience, 2017, 37, 4692-4704.	3.6	169
8	Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion. Journal of Immunology, 2014, 193, 1525-1530.	0.8	149
9	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene, 2019, 38, 390-405.	5.9	149
10	B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death and Disease, 2019, 10, 308.	6.3	143
11	IL-36Î ³ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses. Cancer Cell, 2015, 28, 296-306.	16.8	93
12	PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer. Cellular Physiology and Biochemistry, 2017, 42, 2267-2280.	1.6	92
13	Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clinical Cancer Research, 2018, 24, 4529-4538.	7.0	82
14	Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. Journal of Molecular Medicine, 2016, 94, 535-543.	3.9	81
15	ATF4 Regulates CD4+ T Cell Immune Responses through Metabolic Reprogramming. Cell Reports, 2018, 23, 1754-1766.	6.4	69
16	Impeded Nedd4-1-Mediated Ras Degradation Underlies Ras-Driven Tumorigenesis. Cell Reports, 2014, 7, 871-882.	6.4	66
17	T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. Immunologic Research, 2011, 50, 269-275.	2.9	64
18	Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy. Acta Biomaterialia, 2019, 90, 300-313.	8.3	50

BINFENG LU

#	Article	IF	CITATIONS
19	Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions. Scientific Reports, 2020, 10, 14749.	3.3	44
20	Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment. Oncolmmunology, 2020, 9, 1708064.	4.6	33
21	Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. PLoS ONE, 2018, 13, e0193428.	2.5	32
22	The Molecular Mechanisms That Control Function and Death of Effector CD4 ^{+ T Cells. Immunologic Research, 2006, 36, 275-282.}	2.9	30
23	Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy. Acta Biomaterialia, 2020, 106, 289-300.	8.3	29
24	Targeted codelivery of doxorubicin and IL-36Î ³ expression plasmid for an optimal chemo-gene combination therapy against cancer lung metastasis. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 15, 129-141.	3.3	28
25	LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. Science Advances, 2021, 7, .	10.3	28
26	Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy. Cancer Immunology Research, 2020, 8, 1381-1392.	3.4	26
27	IL-36β Promotes CD8+ T Cell Activation and Antitumor Immune Responses by Activating mTORC1. Frontiers in Immunology, 2019, 10, 1803.	4.8	23
28	The IL-1 family in tumorigenesis and antitumor immunity. Seminars in Cancer Biology, 2022, 86, 280-295.	9.6	22
29	IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses. Frontiers in Immunology, 2020, 11, 634.	4.8	21
30	Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents. Molecular Pharmaceutics, 2018, 15, 5162-5173.	4.6	20
31	Development and application of sensitive, specific, and rapid CRISPR as13â€based diagnosis. Journal of Medical Virology, 2021, 93, 4198-4204.	5.0	20
32	Autophagy Induction and Autophagic Cell Death in Effector T Cells. Autophagy, 2007, 3, 158-159.	9.1	18
33	A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death. Biomaterials, 2021, 270, 120708.	11.4	14
34	Eomes Impedes Durable Response to Tumor Immunotherapy by Inhibiting Stemness, Tissue Residency, and Promoting the Dysfunctional State of Intratumoral CD8+ T Cells. Frontiers in Cell and Developmental Biology, 2021, 9, 640224.	3.7	13
35	CD8+ T cells located in tertiary lymphoid structures are associated with improved prognosis in patients with gastric cancer. Oncology Letters, 2020, 20, 2655-2664.	1.8	13
36	Ginsenoside PPD's Antitumor Effect via Down-Regulation of mTOR Revealed by Super-Resolution Imaging. Molecules, 2017, 22, 486.	3.8	12

BINFENG LU

#	Article	IF	CITATIONS
37	The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 779865.	3.7	11
38	Targeting metabotropic glutamate receptor 4 for cancer immunotherapy. Science Advances, 2021, 7, eabj4226.	10.3	11
39	Interleukin-33 Expression does not Correlate with Survival of Gastric Cancer Patients. Pathology and Oncology Research, 2017, 23, 615-619.	1.9	9
40	High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer: a pooled meta-analysis. Scientific Reports, 2017, 7, 8769.	3.3	7
41	Farnesylthiosalicylic acid-derivatized PEI-based nanocomplex for improved tumor vaccination. Molecular Therapy - Nucleic Acids, 2021, 26, 594-602.	5.1	6
42	Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma. Hepatology Communications, 2022, 6, 1123-1139.	4.3	5
43	Differential Requirement of Beclin 1 for Regulating the Balance of NaÃ ⁻ ve and Activated CD4+ T Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 834.	3.7	2
44	An Essential Role of the RNA Editing Enzyme ADAR1 in T Cell Development Blood, 2009, 114, 917-917.	1.4	1
45	Peripheral Deletion of CD8 T Cells Requires p38 MAPK in Cross-Presenting Dendritic Cells. Journal of Immunology, 2017, 199, 2713-2720.	0.8	0
46	ILâ€17 helps autoimmune th1 responses. FASEB Journal, 2008, 22, 1073.24.	0.5	0
47	Gadd45β Is Important for CD8+T Cell Mediated Tumor Surveillance. FASEB Journal, 2008, 22, 1078.10.	0.5	0
48	Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis. Journal of Immunology Research, 2022, 2022, 1-10.	2.2	0